AA
Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS)
₹104.53
Mkt cap
₹315 Cr
P/E ratio
75.60
P/B
1.97
Div yield
0.00%
ROE
2.75%
ROCE
5.58%
EPS (TTM)
₹1.38
Book value
₹53
52W range
50–108
Sector
Healthcare
Price history
Previous close
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications [1]
NSE AAREYDRUGSBSE 524412
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
−3.08% from high₹105
₹50+107.77% from low₹108
Current
₹104.53
Prev close
₹104.03
Day
+0.48%
Price performance
1D
+0.48%
1W
+5.02%
1M
+10.68%
3M
+18.80%
6M
+94.62%
1Y
+33.11%
YTD
+57.57%
Financials
Revenue, profit & margin
P/E ratio
75.6×
AAREYDRUGS is 119% above the sector median of 34.6×
AAREYDRUGS75.6×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.96 | 57.83 | 76.48 | 210.35 | 126.91 | 105.14 | 133.79 | 108.10 | 102.21 | 84.16 | 96.43 | 189.47 | 44.63 | |
| Expenses | 49.62 | 55.99 | 73.78 | 211.79 | 125.73 | 101.42 | 131.59 | 112.31 | 100.50 | 81.52 | 97.94 | 185.13 | 43.31 | |
| Operating Profit | 1.34 | 1.84 | 2.70 | -1.44 | 1.18 | 3.72 | 2.20 | -4.21 | 1.71 | 2.64 | -1.51 | 4.34 | 1.32 | |
| OPM % | 2.63% | 3.18% | 3.53% | -0.68% | 0.93% | 3.54% | 1.64% | -3.89% | 1.67% | 3.14% | -1.57% | 2.29% | 2.96% | |
| Other Income | 0.70 | 0.84 | 0.29 | 5.14 | 1.58 | 0.02 | 0.68 | 7.54 | 1.55 | 0.79 | 4.18 | -0.43 | 1.72 | |
| Interest | 0.42 | 0.41 | 0.47 | 0.40 | 0.96 | 0.49 | 0.58 | 1.30 | 1.04 | 1.26 | 0.92 | 1.78 | 1.67 | |
| Depreciation | 0.89 | 1.27 | 1.06 | 1.15 | 0.47 | 1.51 | 0.90 | 0.41 | 0.49 | 0.69 | 0.83 | 0.85 | 0.85 | |
| Profit before tax | 0.73 | 1.00 | 1.46 | 2.15 | 1.33 | 1.74 | 1.40 | 1.62 | 1.73 | 1.48 | 0.92 | 1.28 | 0.52 | |
| Tax % | 0.00% | -22.00% | 30.14% | -0.47% | 6.77% | 8.62% | 48.57% | 71.60% | 20.81% | 31.08% | 38.04% | -21.88% | -98.08% | |
| Net Profit | 0.72 | 1.23 | 1.02 | 2.15 | 1.24 | 1.60 | 0.72 | 0.47 | 1.37 | 1.02 | 0.57 | 1.56 | 1.02 | |
| EPS in Rs | 0.28 | 0.48 | 0.40 | 0.77 | 0.44 | 0.57 | 0.25 | 0.17 | 0.48 | 0.36 | 0.20 | 0.55 | 0.36 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +2.04% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 14 Aug '26◦ |
| Earnings day | +2.04% |
| +1 day | −2.04% |
| +5 days | −6.88% |
| +15 days | +16.02% |
| +30 days | +19.14% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Aug 202642.79%Promoter
Promoters42.79%5.08
FIIs4.41%0.40
DIIs1.49%0.13
Public51.31%4.56
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Aarey Drugs | ₹102.13 | 75.62 | 315 | 0.00% | 1 | −25.55% | 45 | −56.33% | 5.58% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Credit ratings6
Announcements5
Disclosure Under Regulation 30 Of SEBI (LODR)Regulations, 2015 11 Sep - 36th AGM scheduled for 30 September 2026; annual report link shared with unregistered email shareholders.Announcement under Regulation 30 (LODR)-Newspaper Publication 9 SepReg. 34 (1) Annual Report. 8 Sep - 36th AGM on 30 September 2026 via VC/OAVM; annual report circulated with related party approvals sought.Notice Of 36Th Annual General Meeting Of The Company For FY 2025-26 8 Sep - 36th AGM on 30 September 2026 via VC/OAVM; annual report circulated, with related party transaction approvals.Intimation Of Book Closure 8 Sep - Registers and share transfer books closed24 September 2026 to 30 September 2026 for 36th AGM.